

Subjects	Age (y)	Sex	Race	BMI	Alcohol (units/month)	Smoking	Medical history	Medication use	Presenting symptoms	Findings DBE	Findings Pathology
1	50	M	Caucasian	20	4-5 units/month	-	1964: resection of small bowel	Methadone	Blood loss	Multiple polyps in proximal small bowel	Peutz Jeghers Polyps
2	38	F	Caucasian	21	-	15 cigarettes/day	BCRA1 gene mutation	Pancreatic enzymes Eye drops	Diarrhea	-	-
3	44	F	na	na	na	na	-	-	Abdominal pain	-	-
4	61	F	Caucasian	24	3 units/day	-	Atrial fibrillation	Proton pump inhibitor, Antiplatelet drug Paracetamol Acenocoumarol Benzodiazepine	Diarrhea; weight loss	Polyp in proximal duodenum	-
5	26	F	Caucasian	na	-	1-10 cigarettes/day	-	-	Abdominal pain	-	-
6	39	M	Black	na	na	na	Diabetes type 2	Metformin Proton pump inhibitor Antiplatelet drug	Abdominal pain	-	-
7	67	F	Caucasian	16	-	Yes	1997: liver failure based on hepatitis B infection wherefore liver transplantation 2005: osteopenia Mild COPD	Proton pump inhibitor Immunosuppressive (Ciclosporin) Calcium/Vitamin D	Iron deficiency anemia	-	-
8	47	F	Caucasian	15	-	-	Fibromyalgia Endometriosis	Budesonide H <sub>2</sub> antagonist Antispasmodic	Diarrhea; weight loss; abdominal pain	-	-
9	54	M	Caucasian	32	6 units/week	-	Hypertension Cholecystectomy Peripheral arterial disease	-	Diarrhea	Erosive abnormalities in jejunum	Reflux esophagitis
10	53	M	Caucasian	na	2	35	2007:	Antiplatelet drug	Iron deficiency	Venectasia	-


					units/day	cigarettes/day	cerebrovascular accident 80% stenosis of a. carotid	Proton pump inhibitor Cholesterol inhibitor Iron supplement	anemia		
11	50	M	Caucasian	21	2 units/day	23 cigarettes/day	Barrett's esophagus	Cholesterol inhibitor Proton pump inhibitor	Weight loss	Small polyp in colon	-
12	55	M	Caucasian	29	-	23 cigarettes/day	Diabetes type 1 hypertension	Insulin pump Proton pump inhibitor Antiplatelet drug Fludrocortisone ACE inhibitor Cholesterol inhibitor Hydrocortisone	Iron deficiency anemia	-	-
13	74	F	Caucasian	na	na	na	Jejunioileal bypass surgery for obesity	Na	Iron deficiency anemia	Extensive ulcerative abnormalities in distal ileum obstructive mass in cecum	Ulcerative lesion in distal ileum *
14	62	M	na	27	1 unit/day	10 cigarettes/day	Peripheral arterial disease	Antiplatelet drug Proton pump inhibitor Iron supplements Cholesterol inhibitor Tramadol	Iron deficiency anemia	-	-

**Supplementary Table 1: Baseline characteristics per individual subject.** na = information is not available; - = no specialties, \*no biopsies were taken during DBE, the mass was diagnosed as a cecum tumor during follow up endoscopy, m = male, f = female, DBE = double balloon enteroscopy


Target	Forward	Reverse	Reference
<b>16S</b>	5'-CGGTGGAATACGTTCCCGG-3'	5'-TACGGCTACCTTGTTACGACTT-3'	<sup>1-3</sup>
<b>UreA</b>	5'-ATGAAACTCACCCCAAAGA-3'	5'-TTCACCTCAAAGAAATGGAAGTGTGA-3'	<sup>4, 5</sup>
<b>VacA S1/S1</b>	5'-ATGGAAATACAACAAACACAC-3'	5'-CTGCTTGAATGCGCCAAAC-3'	Adapted from <sup>6</sup>
<b>ACTB</b>	5'-CTGGAACGGTGAAGGTGACA-3'	5'-AAGGGACTTCCTGTAACAATGCA-3'	<sup>7</sup>

**Supplementary Table S2: Primers used for DNA amplification**


### Supplementary figures




**Supplementary Figure S1. Bacterial abundance, unlike human genomic content, fluctuates along the intestinal tract. (A)** Human *ACTB* primers identify the gene encoding beta-Actin in both human copyDNA (cDNA) and genomic DNA (gDNA) isolated from human colorectal epithelial cancer cell lines CACO2. **(B)** Two representative examples of comparison of bacterial DNA (16S) and human DNA (*ACTB*) along the intestinal tract from two subjects (S1 and S2). 1: distal oesophagus; 2: antrum; 3: proximal duodenum; 4: distal jejunum, 5: proximal ileum; 6: distal ileum; 7: ascending colon; 8: descending colon; 9: rectum.



**Supplementary Figure S2: Abundance of *Enterobacteriaceae* at family level along the gastrointestinal tract** (A) Relative abundance of enterobacteriaceae in mucosal biopsies from a patient with a cecum tumor (S12) is shown. X: missing sample. Green: upper gastrointestinal locations. Yellow: lower gastrointestinal locations (B) Comparison of abundance of *Enterobacteriaceae* at family level between patients, mean $\pm$ SEM of all the GI locations are shown for subjects 1-14. (C) Most important bacteria at family level (>1% abundance) per location in patient with a cecum tumor.




**Supplementary Figure S3: Cluster analysis of taxonomy at family level demonstrating the clustering per patients and the upper and lower digestive tract.** Samples indicated with yellow box were from patient 12, who was characterized *Enterobacteriaceae* dominance. The utmost left sample was a *Helicobacter*-dominated sample from patient 6 (indicated in orange). Blue boxes indicate clustering of two or more samples from one individual patient.



**Supplementary Figure S4: Principal coordinate analysis (PCoA) plot of Bray curtis distances.**

Similar to **Figure 4**, but now the different coloured dots represent different patients. Egg blue dots circled in blue indicate subject S12, dominated by by *Enterobacteriaceae*. In the left cluster (lower GI, circled in yellow), individual patient samples appear to lie closer together than in the right cluster (upper GI, circled in green).



**Supplementary Figure S5. Relative abundance of *Helicobacter* species across the different GI sites.** *Helicobacter* was detected in 9 subjects. The relative abundance of *Helicobacteraceae* as detected by sequencing are shown here for individual GI locations of 7 subjects. Subjects S6 and S14 are shown in Figure 7.



## References

25. Suzuki MT, Taylor LT, DeLong EF. Quantitative analysis of small-subunit rRNA genes in mixed microbial populations via 5'-nuclease assays. *Appl Environ Microbiol.* 2000;66(11):4605-14.
26. Rodes L, Saha S, Tomaro-Duchesneau C, Prakash S. Microencapsulated *Bifidobacterium longum* subsp. *infantis* ATCC 15697 favorably modulates gut microbiota and reduces circulating endotoxins in F344 rats. *Biomed Res Int.* 2014;2014:602832.
27. Furet JP, Firmesse O, Gourmelon M, Bridonneau C, Tap J, Mondot S, et al. Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR. *FEMS Microbiol Ecol.* 2009;68(3):351-62.
28. van Vliet AH, Kuipers EJ, Stoof J, Poppelaars SW, Kusters JG. Acid-responsive gene induction of ammonia-producing enzymes in *Helicobacter pylori* is mediated via a metal-responsive repressor cascade. *Infect Immun.* 2004;72(2):766-73.
29. van Vliet AH, Kuipers EJ, Waidner B, Davies BJ, de Vries N, Penn CW, et al. Nickel-responsive induction of urease expression in *Helicobacter pylori* is mediated at the transcriptional level. *Infect Immun.* 2001;69(8):4891-7.
30. Kim JW, Kim JG, Chae SL, Cha YJ, Park SM. High prevalence of multiple strain colonization of *Helicobacter pylori* in Korean patients: DNA diversity among clinical isolates from the gastric corpus, antrum and duodenum. *Korean J Intern Med.* 2004;19(1):1-9.
31. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.* 2002;3(7):RESEARCH0034.